44.4 Million Estimated to Be Diagnosed With Cervical Cancer by 2069
In the absence of further intervention, in the next 50 years, an estimated 44.4 million women will be diagnosed with cervical cancer globally.
Human Papillomavirus
High-Risk HPV Infection Linked to Increased Risk for CVD in Women
High risk HPV infection is associated with an increased risk for developing CVD.
New HPV Screening Kit Allows Women to Test at Home
To obtain a kit, patients must first answer a few medical history questions to determine if they are appropriate candidates for at-home testing.
Prevalence of Anogenital Warts Declining Across Populations
The prevalence of anogenital warts has decreased, with significant declines observed in specific populations.
HIV & Cancer Risk: Expert Interview
Although rates of AIDS-defining malignancies have declined in recent decades, cancer remains a leading cause of mortality in people living with HIV.
Cisplatin Superior to Cetuximab for HPV+ Oropharyngeal Cancer
For treatment of HPV positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in terms of reduced toxicity and results in worse tumor control.
Update on the Ethics of Mandating HPV Vaccination
Following diagnosis, 66.2% of women with the disease survive 5 or more years.1 HPV causes the majority of cervical cancer cases.
Fewer Parents Have Sexuality, Gender Concerns About HPV Shot
Parents’ concerns about sexuality and gender as reasons for lack of HPV vaccine initiation in their children decreased substantially from 2010 to 2016.
Hispanics With HIV Face Higher Risk for HPV-Related Cancer
But five-year survival was above 50 percent among HIV-infected Hispanics across HPV-related cancer types.
FDA Approves HPV Vaccine for People Through Age 45
US Food and Drug Administration approval of the Gardasil 9 HPV vaccine has been expanded to include people ages 27 through 45.
Next post in Prevention
